For the estimated 700,000 people in the United States who suffer from Crohn’s disease (CD), there are multiple prescription therapies that are available for treating the associated symptoms. The American Gastroenterological Association (AGA) guidelines recommend a step-up treatment paradigm that begins with safer (albeit less efficacious) therapies such as the aminosalicylates, before moving on to more-potent therapies, such as corticosteroids (for acute treatment) and immunosuppressants (for maintenance treatment), and finally the biologics. Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated CD patient populations. Among the newly diagnosed patients, the report provides a quantitative analysis of treatment patterns and share by line of therapy, as well as progression between lines, duration of treatment on each line, and use of concomitant treatment. Among recently treated patients, the report quantifies a drug’s source of business compared with its competitors and details which drugs precede others through an analysis of add-versus-switch patterns. Additional analyses explore persistency and compliance by brand.
Primary patient-level data: Quantitative findings from our analysis of data covering approximately 40 million lives providing the most representative sample of U.S. treatment practice for Medicare and commercially insured patients. This report is delivered as a key findings slide deck and a dashboard that can be accessed using the Internet with claims that are less than six months old at the time of publication.
- Patients who are continuously enrolled for the complete two-year study period must meet the following condition: at least two claims with a diagnosis code for CD (International Classification of Diseases, Ninth Revision [ICD-9] diagnostic codes 555.0, 555.1, 555.2, 555.9) during the study period.
- Quantified lines of therapy analysis showing exact share of each agent in each line of therapy, including rate of progression between lines and length of time patients are on each line.
Newly Diagnosed Patients:
- Patient share by drug class and key products across three lines of therapy, within one year of diagnosis.
- Patient flowchart through one year of treatment for all first-line products, including progression rates and add/switch behavior.
- Polypharmacy and key concomitant therapies by line of therapy.
- Quarterly trending of patient share by line of therapy.
Recently Treated Patients:
- Quarterly snapshot of patient share by drug class and key products.
- Pathway to key therapy flowcharts tracking the preceding therapy patterns for all key therapies, including add/switch behavior.
- Brand source of business including share for continuing, new (switches/adds), and new (initial therapy) business.
- Polypharmacy and key concomitant therapies.
- Drug persistence and compliance.
- Quarterly trending of patient share for all key therapies.